Apai Polyudhapoom
General Practice · Fresno, CANPI 1093885915
Payments from drug & device makers
Across 105 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$275
- Pfizer$211
- Gilead$191
- AbbVie$186
- AstraZeneca$180
- Merck$132
- plus $902 from 15 others
What the payments were for
- Food & beverage$2,078100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 12 | $275 |
| Pfizer | 11 | $211 |
| Gilead | 5 | $191 |
| AbbVie | 10 | $186 |
| AstraZeneca | 10 | $180 |
| Merck | 7 | $132 |
| Biohaven Pharmaceuticals, Inc. | 9 | $131 |
| Lilly USA, LLC | 7 | $126 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $111 |
| Bayer | 5 | $111 |
| Boehringer Ingelheim | 6 | $97 |
| GSK | 4 | $87 |
| Dexcom, Inc. | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| VBI Vaccine (delaware) Inc. | 2 | $39 |
| Dynavax Technologies Corporation | 2 | $34 |
| Johnson & Johnson | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Alkermes, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$103
How this compares
$2,078 in reported general payments places this provider in the 90th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $25,718 |
| TradjentaLinagliptin | 18 | $13,182 |
| JanuviaSitagliptin Phosphate | 15 | $10,097 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,263 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $7,758 |
| Ventolin HfaAlbuterol Sulfate | 44 | $2,285 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,815 |
| Gabapentin | 149 | $1,056 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $995 |
| Ultiguard Safepack-Pen NeedlePen Needle, Diabetic,disp Unit | 17 | $955 |
| Allopurinol | 154 | $905 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 15 | $680 |
| Montelukast Sodium | 86 | $666 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $617 |
| Famotidine | 65 | $524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia | $132 | $35,81558 claims |
| Boehringer IngelheimTradjenta | $97 | $13,18218 claims |
| GSKTrelegy Ellipta | $87 | $9,26315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 12,963 general practice providers in California.
Other general practice in Fresno
- Ryan DunlopFresno$151K
- Hipolito MarianoFresno$133K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.